Navigation Links
New PICC Mimics Nature
Date:7/1/2009

A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces. r4 Vascular designed the catheter to have a biomimetic surface that mimics the natural glycocalyx layer on endothelial tissues.

Maple Grove, MN (Vocus) July 1, 2009 -- A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces. r4 Vascular designed the catheter to have a biomimetic surface that mimics the natural glycocalyx layer on endothelial tissues. Laboratory tests prove that mimicking the glycocalyx layer can dramatically reduce thrombus formation on the catheter surfaces.

r4 Vascular recently gained FDA clearance to launch their first catheter based on this Biomimetic technology. It will be available beginning June 30, 2009 as the Zeus™ Coated CT PICC.

According to Gail Sansivero, MS, ANP, Vascular and Interventional Radiology Nurse Practitioner, Albany Medical Center, "Thrombus can be a real problem for patients with PICCs. Biologically, a patient responds to a catheter insertion within 24 hours by developing bio-film. Thrombus can later amass on the catheter surface, within the catheter and/or become adherent to the vein. The thrombus can cause catheter occlusion, serve as a nidus for infection, and even dislodge into the bloodstream, putting patients at risk for deep vein thrombosis (DVT) or pulmonary embolism (PE)."

Today, clinicians typically try to avoid thrombus occlusion by instilling heparin into catheters between uses. However, many patients are allergic to heparin, which can cause heparin-induced thrombocytopenia (HIT). Some PICC manufacturers have addressed the thrombus problem by affixing valves to their catheters, which can limit placement methods and reliable blood sample withdrawal through the catheter. r4 Vascular engineers took a cue from stealth technologies instead, approaching the problem by camouflaging the catheter in a Biomimetic coating. Laboratory testing has shown the coating to be so effective that it is the first nonvalved PICC to receive FDA clearance for saline-only maintenance.

According to r4 Vascular's CEO, Michael Sarajian, "In speaking with PICC clinicians, we learned that valved PICCs can be difficult to place and unreliable in use. By approaching the thrombus problem scientifically, r4 has developed a nonvalved PICC that enables over-the-wire placement and reliable blood draws while reducing thrombus formation for a longer service life."

r4 Vascular is a privately-held vascular access company driving innovation in vascular access medical technology. r4's passion is "uncomplicating" venous access, chemotherapy, and drug delivery, through product improvements that help catheters remain patent and effective, with reduced risk of complications.

John Zawacki
r4 Vascular, Inc.
763-494-8400
Fax: 763-494-8484
www.r4vascular.com

###

Read the full story at http://www.prweb.com/releases/r4_Vascular/biomimetic/prweb2596764.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lab on a chip mimics brain chemistry
2. Virus mimics human protein to hijack cell division machinery
3. Yeast mimics severity of mutations leading to fatal childhood illness
4. Gene signature spells poor outcome
5. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
6. Revealing the workings of Mother Natures blowtorch
7. APHA Urges President Bush Not To Veto CHIP; Were Only One Signature Away from Protecting the Health of Our Children
8. DuPont Pledges $250,000 to Nature Conservancy for Water Quality Initiative
9. Natures Baby Organics Announces Ah-Choo! Chest Rub
10. National Nature Made(R) Survey Finds U.S. Adults Are Concerned About Heart Disease but May not be Managing Their Risk
11. New neuroimaging study identifies brain signature for cigarette cravings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New PICC Mimics Nature
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., ... to announce it has joined the National Association for Home Care and Hospice ... ill, disabled, and dying Americans of all ages and the caregiver who provide ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival ... wardrobe. However, for those self-conscious about a double chin, this means more anxiety than ... solution. , “For most people, a double chin is undesirable,” Dr. Goldman said, ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... successfully passed early toxicology and efficacy studies. The company ... target a specific protein, MAGE A, in an effort ... cancer. After 4 weeks of treatment ... show very little toxicity in a full toxicology report ...
Breaking Medicine Technology: